

STRIDES PHARMA ASIA PTE. LIMITED
BALANCE SHEET AS AT 31 March 2024

Amount in USD

	Particulars	Note No.	31-Mar-24	31-Mar-23
I.	Equity and Liabilities			
	1. Shareholders' Funds			
	(a) Share Capital	1	175,329,360	175,329,360
	(b) Reserves and Surplus	2	27,185,180	24,480,048
			202,514,540	199,809,408
	2. Current liabilities			
	(a) Trade payables	3	368,615	7,847,866
	(b) Other Current Liabilities	4	2,059,363	1,714,408
	(c) Short-term provisions	5	52,568	52,569
			2,480,547	9,614,843
	TOTAL		204,995,087	209,424,251
II.	Assets			
	1. Non-Current Assets			
	(a) Non- current investments	6	200,952,514	208,709,137
			200,952,514	208,709,137
	2. Current assets			
	(a) Trade Receivables	7	-	497
	(b) Cash and Cash Equivalent	8	130,868	391,281
	(c) Short-term Loans and Advances	9	3,911,705	323,090
	(d) Other Current Assets	10	-	246
			4,042,573	715,114
	TOTAL		204,995,087	209,424,251

STRIDES PHARMA ASIA PTE. LIMITED
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2024

Amount in USD

Particulars	Note No.	31-Mar-24	31-Mar-23
Other Income	11	6,585,578	2,389,421
Total Revenue		6,585,578	2,389,421
Expenses			
Other Expenses	12	313,142	137,725
Finance costs	13	3,105	2,770
Total		316,248	140,496
Profit / (Loss) for the year after tax		6,269,330	2,248,926

STRIDES PHARMA ASIA PTE. LIMITED
Notes forming part of the financial statements

Note

No.

1	Share capital		
	Particulars	31-Mar-24	31-Mar-23
	Issued, subscribed and fully paid-up		
	Equity share capital	175,329,360	175,329,360
	Total	175,329,360	175,329,360
2	Reserves and surplus		
	Particulars	31-Mar-24	31-Mar-23
	1. Capital Reserve	(1,122,154)	(1,122,154)
	2. Surplus in Statement of Profit and Loss		
	Opening Balance	25,602,204	23,353,276
	Add: Profit / (Loss) for the year	6,269,330	2,248,926
	Less: Equity dividend	(3,564,200)	-
	Closing balance	27,185,180	24,480,048
	Total	27,185,180	24,480,048
3	Trade payables		
	Particulars	31-Mar-24	31-Mar-23
	Other than acceptances	368,615	7,847,866
	Total	368,615	7,847,866
4	Other current liabilities		
	Particulars	31-Mar-24	31-Mar-23
	Payable to group entities	-	1,714,048
	Dividend Payable	2,059,000	-
	Other payables:		
	- Statutory remittances	363	360
	Total	2,059,363	1,714,408
5	Short-term provisions		
	Particulars	31-Mar-24	31-Mar-23
	Provision - Others:		
	- Provision for tax (net of advance tax)	52,568	52,569
	Total	52,568	52,569
6	Non - current investments		
	Particulars	31-Mar-24	31-Mar-23
	Strides Pharma Global Pte Limited	196,481,042	202,861,479
	Stelis Biopharma (Malaysia) SDN BHD	-	1,376,186
	Trinity Pharma (Pty) Limited	4,471,472	4,471,472
	Total	200,952,514	208,709,137
7	Trade receivables		
	Particulars	31-Mar-24	31-Mar-23
	Unsecured, considered good		
	Outstanding for a period exceeding six months from the date they were due for payment		
	Others		
	- Unsecured considered good	-	497
	- Doubtful	-	497
	Less: Provision for doubtful trade receivables	-	-
	Total	-	497

8 Cash and cash equivalents

Particulars	31-Mar-24	31-Mar-23
Bank balance	130,868	391,281
Total	130,868	391,281

9 Short-term loans and advances**Amount in USD**

Particulars	31-Mar-24	31-Mar-23
Unsecured, considered good		
Receivable from related parties	3,911,705	323,090
Total	3,911,705	323,090

10 Other Current Assets

Particulars	31-Mar-24	31-Mar-23
Prepaid expense	-	246
Total	-	246

11 Other Income

Particulars	31-Mar-24	31-Mar-23
Profit/(Loss) on sale of investment	6,546,705	2,353,162
Other Income- Guarantee commission	11,237	8,688
Interest Income	27,636	27,571
Total	6,585,578	2,389,421

12 Other Expenses

Particulars	31-Mar-24	31-Mar-23
Membership fees and subscription	246	654
Exchange fluctuation loss (net)	12,618	87,221
Professional fees	90,334	18,826
Rates and taxes	34,460	524
Payment to Auditors - For Statutory Audit	16,971	23,187
Provision for impairment of investment	150,678	-
Director sitting fees	6,000	6,000
Support service expenses- Arcolab	1,338	1,313
Others	497	-
Total	313,142	137,725

13 Finance Cost

Particulars	31-Mar-24	31-Mar-23
Bank Charges & Commission	3,105	2,770
Total	3,105	2,770